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1 Introduction
The most prominent feature of neonatal clinical pharma-
cology is huge variability in pharmacokinetics and phar-
macodynamics of frequently used medicines due to rapid
growth and maturation. This variability is further aggra-
vated by other covariates such as disease characteristics,
co-medication or pharmacogenetics. A thorough under-
standing of developmental changes affecting pharmacoki-
netics (absorption, distribution, metabolism, elimination) in
neonates is essential to provide accurate dose adjustments.
While there is increasing knowledge on the impact of these
maturational changes on pharmacokinetics, there is cur-
rently very limited data on developmental pharmacody-
namics [1]. The fact that adverse drug events in neonates
are common and may have lifelong consequences, focused
pharmacovigilance is urgently needed. Even more, phar-
macovigilance should stimulate us to try unveiling the
underlying mechanisms of adverse events, and to use this
newly acquired knowledge in redesigning the product
development approach in neonates.
2 A Mechanism to Explain Ototoxicity in Neonates
Participating in the NEMO Trial
The urgent need for a pharmacovigilance program in
neonates specifically focusing on ototoxicity has recently
been highlighted in the NEMO (treatment of NEonatal
seizures with Medication Off-patent) trial. The aim of this
study was to treat resistant neonatal seizures in asphyxia
with different, relatively high, doses of bumetanide
(0.05–0.3 mg/kg every 12 h) after a loading dose of phe-
nobarbital. This clinical trial was stopped early because of
lack of efficacy and a high incidence of serious adverse
events, including severe hearing impairments in three out
of 11 survivors, unrelated to measured trough concentra-
tions of aminoglycosides [2].
We would like to propose a pharmacological mechanism
that might explain why neonates, who are treated with
bumetanide, are more prone to develop ototoxicity and to
propose considering animal studies that will assess hearing
related safety aspects in addition to pharmacovigilance.
In vitro studies have shown that aminoglycosides bind
tightly to acidic phospholipids and alter intracellular traf-
ficking. While this binding may potentially occur at any
cell, it is much more pronounced at cochlear hair cells due
to expression of specific ligands (like megalin and the co-
localized cubilin) at the brush border of the cells in the
inner ear. The subsequent process of endocytosis also
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involves megalin as multiligand endocytic receptor. Intra-
cellular accumulation subsequently will induce processes
that may result in cell death through apoptosis. Besides
endocytosis, there are also endocytosis-independent path-
ways using cation channels [3]. Interestingly, in vitro
models have documented that loop diuretics like fur-
osemide or bumetanide enhance aminoglycoside uptake
through hyperpolarization of the cell, increasing cation
influx cation force [4]. It is therefore reasonable to
hypothesize that in the NEMO trial the pharmacodynamic
effect of bumetanide stimulated a cation influx force that
resulted in intracellular aminoglycoside accumulation,
subsequent toxicity, and unavoidable cell death [4]. In
addition, based on animal studies, the mechanism of
megalin-independent ion channel driven accumulation of
aminoglycosides has also been suggested to explain the
synergism between exposure to noise and aminoglycoside
toxicity [5]. Exposure to loud noise also increases the
probability of a current through mechano-electrical trans-
duction using ion channels which—in turn—will result in a
higher intracellular aminoglycoside accumulation within
the hair cells, subsequent cell death, and ultimately hearing
loss.
The outcome of the NEMO trial is unfortunate but is in
line with already available observations on furosemide
related hearing impairments [6]. While the aforementioned
mechanism has only been reported recently, the epidemi-
ological data between loop diuretics and hearing impair-
ment have been reported decades ago, using much lower
doses of bumetanide. In retrospect, this association could
have been considered and assessed more rigorously in a
maturational animal model before conducting clinical trials
in humans.
3 How Should This Help us to Improve Product
Development in Neonates?
Neonates are still in an urgent need for safer and more
effective drugs for their diseases. This is also true for
neonatal seizures because this is a very relevant disease
entity which deserves better clinical management and drug
choices [1]. However, effective product development in
neonates necessitates multidisciplinary collaboration, and
we claim that is up to us—clinicians—to reach out to other
disciplines trying to stimulate them to build preclinical
models tailored to explore the mechanism of disease enti-
ties and compounds to treat these entities (e.g., matura-
tional ototoxicity [5]) in neonates.
Decisions on compound, indication, timing and dosing
for a clinical trial in human neonates should be based on a
multidisciplinary team decision (including developmental
toxicologists, clinical pharmacologists, and trial
specialists) and must take into account: (a) clinical needs,
(b) available epidemiological data, and (c) evidence sup-
ported by juvenile animal studies in assuring sufficient
efficacy and safety.
The good news is that these kinds of multidisciplinary
collaborations with a focus on neonatal drug development
are currently emerging. As part of the Critical Path Initiative
(C-path), the International Neonatal Consortium (INC) has
recently been developed to serve as a multidisciplinary
forum for the neonatal community to develop consensus
statements (e.g., standardization ofmethods, standard of care
consensus statements, population specific biomarkers,
modelling approaches, trial designs, clinical outcome
assessment tools, formulation issues) with the ultimate goal
to improve neonatal medicines development [7]. Similarly,
the Developmental and Reproductive Toxicology (DART)
technical committee as part of the Health and Environmental
Sciences Institute (HESI) scientific initiative has launched a
project to identify the available non-clinical models to
facilitate the optimal use of nonclinical approaches for
neonatal therapeutics. This initiative aims to collect and
report on an extensive survey on nonclinical models of
neonatal pediatric therapeutics. In the same effort, this ini-
tiative also aims to establish a framework for evaluation and
implementation of nonclinical neonatal models, to improve
the understanding of comparative, inter-species maturation,
and to optimize dose selection in neonates [8, 9].
At least multidisciplinary approaches from pre-clinical
to clinical studies in neonates may also reshape our
approach to medicine development in neonates, from
exploratory approaches to focused product development
driven by their needs (diseases), characteristics (matura-
tional physiology) and tolerance (maturational toxicology).
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